Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05906836 · ClinicalTrials.gov registry record · Phase 1

A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants

A Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
28
Enrollment target
1
Study location

NCT05906836: Completed Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

NCT05906836 is a Phase 1 study of Healthy that has completed, run by Eli Lilly and Company. The registered enrollment target is 28 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05906836, a Phase 1 study of Healthy, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

The main purpose of this study is to determine the effect of selpercatinib on the levels of rosuvastatin in the blood stream in healthy participants. This study also evaluated the safety and tolerability of rosuvastatin when administered in combination with selpercatinib in healthy participants. This study will last up to approximately 26 days excluding screening period.

Primary Outcome

PK: Cmax of Rosuvastatin was reported.

Conditions Studied

Healthy

Interventions

  • DRUG Rosuvastatin
  • DRUG Selpercatinib

Study Locations (1)

Texas

  • Labcorp Clinical Research LP - Dallas

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2023-07-27
Est. Completion 2023-10-31
Phase Phase 1
Eli Lilly and Company

1,341 total trials

What the finished NCT05906836 record still lists

NCT05906836 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Rosuvastatin is the first listed.

NCT05906836 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05906836 about?

NCT05906836 is a clinical study titled "A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants". The main purpose of this study is to determine the effect of selpercatinib on the levels of rosuvastatin in the blood stream in healthy participants. This study also evaluated the safety and tolerability of rosuvastatin when administered in combination with selpercatinib in healthy participants. Thi...

What is the current status of trial NCT05906836?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2023-07-27. Estimated completion is 2023-10-31.

What conditions does trial NCT05906836 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT05906836?

The interventions under investigation include: Rosuvastatin (DRUG), Selpercatinib (DRUG).

Who is sponsoring clinical trial NCT05906836?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05906836 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05906836's enrollment target sits among peer trials

28 736th of 1090 higher than 340 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05906836, the US trial registry maintained by the National Library of Medicine. NCT05906836 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.